bentracimab bentracimab bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a p2y12 inhibitor and is sold under the brand name brilinta among others). it is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. it is not commercially available. bentracimabmonoclonal antibodytypefab fragmentsourcehumantargetticagrelor, ar-c124910xx (the active metabolite)clinical dataother namespb2452, medi2452routes ofadministrationintravenous infusionatc codenonelegal statuslegal status investigational identifierscas number2260568-31-6pubchem sid405226665drugbankdb16659unii1tbm83qr9skeggd11799chemical and physical dataformulac2095h3240n560o674s12molar mass47440.93 g·mol−1